232 related articles for article (PubMed ID: 34830456)
1. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract][Full Text] [Related]
2. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
Stygar D; Muravitskaya N; Eriksson B; Eriksson H; Sahlin L
Reprod Biol Endocrinol; 2003 May; 1():40. PubMed ID: 12777179
[TBL] [Abstract][Full Text] [Related]
3. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.
Marrero-Alonso J; Morales A; García Marrero B; Boto A; Marín R; Cury D; Gómez T; Fernández-Pérez L; Lahoz F; Díaz M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):898-910. PubMed ID: 23727370
[TBL] [Abstract][Full Text] [Related]
4. Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues.
Wong KY; Zhou L; Yu W; Poon CC; Xiao H; Chan CO; Mok DK; Wong MS
J Ethnopharmacol; 2021 Jul; 275():114096. PubMed ID: 33823166
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and in-silico study of novel triarylethylene analogs with dual anti-estrogenic and serotonergic activity.
Mostafa T; Albeir M; Wober J; Abadi A; Salama I; Ahmed NS
Drug Dev Res; 2024 Feb; 85(1):e22127. PubMed ID: 37877739
[TBL] [Abstract][Full Text] [Related]
6. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
[TBL] [Abstract][Full Text] [Related]
7. [Effect of selective estrogen receptor modulators on estrogen-sensitive tissues].
Jirecek S; Pavo I; Huber JC
Gynakol Geburtshilfliche Rundsch; 1999; 39(4):184-90. PubMed ID: 10629380
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
Lv W; Liu J; Skaar TC; O'Neill E; Yu G; Flockhart DA; Cushman M
J Med Chem; 2016 Jan; 59(1):157-70. PubMed ID: 26704594
[TBL] [Abstract][Full Text] [Related]
9. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation.
Sreeja S; Santhosh Kumar TR; Lakshmi BS; Sreeja S
J Nutr Biochem; 2012 Jul; 23(7):725-32. PubMed ID: 21839626
[TBL] [Abstract][Full Text] [Related]
10. Structure-Activity Relationships of Triphenylethylene Derivatives and Their Evaluation as Anticancer and Antiviral Agents.
Ahmed NS; El-Nakib HE; Ramsis MM; Albably NO; Wober J; Weigand JJ; Schwedtmann K; Zierau O; Abadi AH
ACS Omega; 2023 Jul; 8(29):25903-25923. PubMed ID: 37521647
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
13. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
14. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
15. Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative Breast Cancer Cell Lines.
Hassan AS; Wober J; Vollmer G; Abadi AH; Ahmed NS
ChemMedChem; 2022 Apr; 17(7):e202100720. PubMed ID: 35076180
[TBL] [Abstract][Full Text] [Related]
16. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
17. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
18. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells.
Bramlett KS; Burris TP
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):27-34. PubMed ID: 12943742
[TBL] [Abstract][Full Text] [Related]
19. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
20. Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions.
Laxmi YR; Liu X; Suzuki N; Kim SY; Okamoto K; Kim HJ; Zhang G; Chen JJ; Okamoto Y; Shibutani S
Int J Cancer; 2010 Oct; 127(7):1718-26. PubMed ID: 20073065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
